Sirolimus alone for low platelet counts from antiphospholipid antibodies
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had positive antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, or anti-b2GP1) on at least two tests taken 12 weeks apart.
- Your platelet count has been between 30 and 100 billion per liter for at least 2 weeks.
- If you take prednisone or similar steroids, the dose must be less than 10 mg per day and stable for at least 2 weeks.
- If you take hydroxychloroquine, the dose must be less than 400 mg per day and stable for at least 1 month.
- You must not have taken certain other platelet-raising or immune-suppressing drugs (like romiplostim, intravenous immunoglobulin, rituximab) for a period equal to 5 times their half-life before starting.
- You do not have other connective tissue diseases (like lupus), active infections, major bleeding, recent clots, or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This study tests whether the drug sirolimus (Rapamune) is safe and effective for people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may offer a new option for those whose current treatment is stable.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Hear when a new Thrombocytopaenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.